Last updated: August 10, 2026
Rilutek is the original branded formulation of riluzole, an oral therapy for amyotrophic lateral sclerosis (ALS). Its commercial profile is that of a mature, largely genericized product: FDA approval and market leadership established the category, but tablet patent and regulatory exclusivity have expired, leaving price, distribution, adherence, and formulation differentiation as the primary value drivers. Sanofi does not separately disclose Rilutek revenue, so its financial trajectory must be inferred from generic erosion, the small ALS population, and competition from newer riluzole delivery systems and ALS therapies.
What is Rilutek and how does it generate revenue?
Rilutek contains riluzole, a benzothiazole compound approved in the United States as a 50 mg tablet for ALS. The FDA approved the product on December 12, 1995, under NDA 20-599. Its approved use is to extend survival or the time to tracheostomy in patients with ALS.[1]
The product’s commercial economics depend on several factors:
| Factor |
Rilutek impact |
| Therapeutic area |
ALS, a rare and serious neurodegenerative disease |
| Active ingredient |
Riluzole |
| Original dosage form |
50 mg immediate-release tablet |
| U.S. approval |
December 12, 1995 |
| Current competitive status |
Generic riluzole tablets available |
| Core differentiation |
Brand recognition, physician familiarity, supply reliability |
| Revenue disclosure |
Not reported separately by Sanofi |
| Main commercial risk |
Generic substitution and lower tablet pricing |
| Growth opportunity |
Limited for the original tablet; greater potential in differentiated delivery systems |
Rilutek’s clinical value is supported by the original randomized trial that showed a modest survival benefit, particularly in relation to tracheostomy-free survival.[2] The product is not a curative therapy and has a limited effect on disease progression. That clinical profile restricts pricing power compared with newer medicines that offer broader functional or survival benefits.
When did Rilutek lose exclusivity?
Rilutek lost its practical market exclusivity years ago. The product’s five-year U.S. new chemical entity exclusivity would have ended in December 2000. Any relevant compound patent protection also expired before the current generic market matured.
The commercial milestones are:
| Date |
Event |
| December 12, 1995 |
FDA approval of Rilutek tablets |
| December 2000 |
Expiration of five-year NCE exclusivity |
| 2000s |
Generic riluzole tablets entered the U.S. market |
| September 2018 |
FDA approval of Tiglutik, a riluzole oral suspension |
| November 2020 |
FDA approval of Exservan, a riluzole oral film |
| 2020s |
Rilutek competes in a mature genericized tablet market |
Rilutek does not have the exclusivity profile of a current branded specialty product. The principal commercial question is no longer whether generic entry is possible. It is how much of the remaining branded volume can be retained through physician preference, patient continuity, payer coverage, and supply-chain positioning.
What is the Orange Book status of Rilutek?
Rilutek is listed in the FDA Orange Book as the reference listed drug for riluzole tablets. The original product is associated with NDA 20-599. The standard 50 mg tablet is exposed to approved abbreviated new drug applications and generic substitution.
The Orange Book position has four commercial consequences:
- Generic manufacturers can rely on the reference product’s safety and efficacy findings through the ANDA pathway.
- Generic tablets can compete directly with Rilutek on the same active ingredient, strength, and dosage form.
- A tablet formulation patent does not currently provide a meaningful barrier to substitution.
- Any remaining brand value comes primarily from commercial execution rather than enforceable exclusivity.
Rilutek’s position differs from products protected by active Orange Book patents covering dosage forms, release profiles, or methods of use. The original tablet has no comparable current patent barrier that would materially delay generic competition.
What patents protect Rilutek?
The original riluzole compound and Rilutek tablet formulation are no longer protected by commercially meaningful U.S. exclusivity. The compound patent estate was developed around riluzole and its pharmaceutical use, but those rights have expired.
The relevant protection categories are:
| Protection category |
Rilutek status |
| Compound patent |
Expired |
| Original tablet formulation |
Expired or no longer commercially blocking |
| FDA NCE exclusivity |
Expired |
| Pediatric exclusivity |
No current exclusivity barrier |
| Method-of-use patents |
No known active claim that materially blocks generic tablet entry |
| Current Orange Book patent barrier |
None of practical commercial significance |
| Regulatory reference product status |
Remains relevant for ANDA approval |
This does not mean that every riluzole-related patent worldwide has expired. Later patents may cover manufacturing processes, specific formulations, oral films, suspensions, packaging, or other delivery technologies. Those patents do not restore exclusivity to the original Rilutek tablet.
What formulations are protected in the riluzole market?
The most important commercial shift has been the expansion from conventional tablets into formulations designed for patients with swallowing difficulties.
Rilutek tablets
Rilutek is a conventional 50 mg tablet. Generic substitution is straightforward, and the dosage form offers limited protection against price competition. The tablet remains relevant because it is familiar, inexpensive, and widely distributed.
Tiglutik oral suspension
Tiglutik is a riluzole oral suspension approved in 2018. It addresses patients who cannot easily swallow tablets. Its differentiation is primarily formulation and administration convenience, not a new active ingredient.
Tiglutik can preserve branded pricing because an oral suspension is not identical to a standard tablet for substitution purposes. Its commercial opportunity is constrained by the relatively small ALS population and by the potential availability of other liquid or compounded riluzole options.
Exservan oral film
Exservan is a riluzole oral film approved in 2020. The film dissolves on the tongue and is designed for patients with dysphagia. The product creates a differentiated route to market because it is not a conventional tablet and may improve administration for a clinically important subgroup.
Exservan competes with both Rilutek and Tiglutik for riluzole-treated patients. Its value depends on reimbursement, patient access, specialty-pharmacy support, and the extent to which prescribers switch patients from lower-cost tablets.
How strong is the Rilutek patent estate?
The current Rilutek patent estate is weak as an exclusivity platform and moderate as a commercial brand platform.
The patent estate is weak because:
- The active ingredient is long genericized.
- The original tablet is directly exposed to ANDA competition.
- The FDA’s reference product framework facilitates generic approval.
- No active Orange Book patent appears to block standard riluzole tablets.
The brand retains limited commercial strength because:
- ALS treatment is concentrated among specialist neurologists.
- Physicians may continue existing patients on a familiar product.
- Medication continuity can matter in a progressive disease.
- Sanofi has established manufacturing, distribution, and regulatory infrastructure.
- Some payers may prefer generic tablets but still reimburse branded products under restricted conditions.
The economic value of the Rilutek name therefore comes from residual demand and channel execution, not from patent leverage.
Which companies are challenging Rilutek?
Generic pharmaceutical companies challenge Rilutek through ANDAs rather than through a high-value Paragraph IV campaign. Once the relevant patent and exclusivity barriers expired, manufacturers could seek approval for riluzole tablets using the standard generic pathway.
The competitive set includes:
| Competitor |
Dosage form |
Competitive relevance |
| Generic riluzole manufacturers |
50 mg tablets |
Direct substitution for Rilutek |
| Tiglutik |
Oral suspension |
Differentiated liquid formulation |
| Exservan |
Oral film |
Differentiated dysphagia-oriented formulation |
| Compounded riluzole |
Liquid or other extemporaneous forms |
Potential price and access alternative |
| Radicava/Radicava ORS |
Intravenous or oral edaravone |
Different active ingredient and treatment approach |
The most direct threat is generic riluzole tablets. Tiglutik and Exservan are not conventional generic copies of Rilutek because their dosage forms differ. They compete for the same active-ingredient treatment market while relying on formulation differentiation.
What is the Paragraph IV risk for Rilutek?
Paragraph IV litigation risk is low for the original Rilutek tablet because there is no current patent barrier that would normally support a meaningful infringement dispute. A generic applicant would have little commercial reason to pursue a costly Paragraph IV challenge against expired or nonblocking rights.
The relevant risk has shifted to later riluzole formulations. Oral suspension and oral film products may have formulation, manufacturing, or use patents that could support patent litigation if a directly substitutable product is filed. The litigation profile for those products must be evaluated separately from Rilutek.
A generic launch scenario for Rilutek is therefore uncomplicated:
- An ANDA applicant demonstrates pharmaceutical equivalence and bioequivalence.
- FDA grants approval.
- State substitution rules and payer formularies determine conversion from Rilutek.
- Multiple suppliers create price pressure.
- The branded product retains a smaller, less price-sensitive segment.
What is the FDA regulatory status of Rilutek?
Rilutek remains an FDA-approved treatment for ALS. The regulatory status is mature rather than expanding. No new indication has materially changed the product’s market size.
The key regulatory characteristics are:
- Approved active ingredient: riluzole
- Approved tablet strength: 50 mg
- Indication: ALS
- Regulatory pathway: original NDA
- Generic pathway: ANDA approvals for equivalent tablets
- Safety monitoring: liver function abnormalities, including transaminase elevations, remain important label considerations
- Administration limitation: standard tablets can be difficult for patients with dysphagia
The FDA-approved oral suspension and oral film products expand administration options, but they do not create a broader disease market. They divide existing riluzole demand across dosage forms.
What patent litigation affects Rilutek?
Rilutek itself is not associated with a current high-value patent litigation narrative comparable with heavily litigated branded drugs. The principal legal event was the historic loss of exclusivity and subsequent generic entry.
Litigation exposure is more relevant to differentiated riluzole products. A manufacturer of a competing suspension or oral film could face claims relating to:
- Film composition and dissolution characteristics
- Suspension stability and dose uniformity
- Packaging and administration devices
- Manufacturing processes
- Patient populations with swallowing impairment
- Formulation-specific methods of use
Those disputes would affect the commercial positions of Tiglutik or Exservan rather than restore patent protection to Rilutek tablets.
What licensing deals affect the riluzole market?
The riluzole market includes product ownership and commercialization arrangements beyond the original Rilutek brand.
Sanofi has historically commercialized Rilutek in the United States. Tiglutik was developed and commercialized by ITF Pharma, while Exservan was developed by Aquestive Therapeutics and commercialized through a partnership with Mitsubishi Tanabe Pharma America.[3][4]
These arrangements matter because the primary value in modern riluzole products lies in:
- Formulation technology
- Patient access programs
- Specialty distribution
- Neurology sales forces
- Reimbursement execution
- Manufacturing know-how
A new entrant would need more than an approved riluzole formulation. It would need access to ALS specialists, reliable supply, payer coverage, and patient-support infrastructure.
How does Rilutek compare with newer ALS drugs?
Rilutek is a low-cost oral standard with a long clinical history. Newer ALS products compete on different clinical and commercial attributes.
| Product |
Active ingredient |
Administration |
Market position |
| Rilutek |
Riluzole |
Tablet |
Original branded riluzole product |
| Generic riluzole |
Riluzole |
Tablet |
Lowest-cost direct substitute |
| Tiglutik |
Riluzole |
Oral suspension |
Liquid administration option |
| Exservan |
Riluzole |
Oral film |
Dysphagia-oriented formulation |
| Radicava |
Edaravone |
Intravenous infusion |
Different ALS therapy |
| Radicava ORS |
Edaravone |
Oral suspension |
Oral alternative to infusion |
| Tofersen |
Tofersen |
Intrathecal injection |
Genetically targeted therapy for SOD1 mutation ALS |
Radicava and Tofersen do not directly replace Rilutek for every patient. Their clinical differentiation and pricing can support larger revenue per treated patient, while Rilutek remains exposed to generic economics.
What is Rilutek’s revenue exposure and financial trajectory?
Sanofi does not report Rilutek as a standalone revenue line in its public financial statements. The product is grouped within broader pharmaceutical revenue categories, making precise annual sales unavailable from company disclosures.[5]
The likely financial trajectory is:
| Period |
Financial condition |
| 1995-2000 |
High-margin originator phase supported by NCE exclusivity |
| 2000s |
Generic entry and rapid price erosion |
| 2010s |
Mature branded product with declining tablet economics |
| 2018 onward |
Formulation competition from oral suspension |
| 2020 onward |
Further competition from oral film |
| Current mature phase |
Residual branded revenue, limited organic growth, low patent value |
Revenue exposure is limited in the context of Sanofi’s overall portfolio. Rilutek is not a major driver of Sanofi’s consolidated sales compared with immunology, vaccines, diabetes, rare disease, and specialty-care products.
The product can still generate cash flow because the clinical market is stable and manufacturing costs for tablets are relatively low. Gross margin is likely pressured by generic pricing and contracting, but a mature product can remain profitable if fixed commercial costs are controlled.
The stronger financial opportunity in riluzole is in differentiated formulations. Oral suspension and oral film products can command higher prices than generic tablets, but they also carry greater manufacturing, regulatory, and market-access costs. Their net value depends on whether they expand treated volume or mainly shift patients from an existing riluzole product.
What generic entry risks exist for Rilutek?
Generic entry risk is already realized rather than prospective. The original tablet faces structural erosion from:
- Multiple approved generic suppliers
- Pharmacy substitution
- Payer tiering
- Specialty-pharmacy purchasing pressure
- Low switching costs for stable tablet users
- Absence of current patent protection
Remaining brand volume is most vulnerable when payers mandate generic substitution or impose higher copayments for Rilutek. The brand may retain patients who have stable supply, physician preference, or insurance coverage, but those factors do not support long-term pricing growth.
The principal future risk is not a new generic version of Rilutek. It is continued migration toward lower-cost generic tablets and competition from alternative riluzole dosage forms.
What geographic coverage does Rilutek have?
Rilutek has historically been marketed in major regulated markets, including the United States and Europe, subject to local approvals, pricing rules, and reimbursement systems. Geographic revenue is difficult to isolate because Sanofi does not separately report Rilutek sales by country.
The U.S. market has the clearest generic substitution framework through Orange Book-listed reference product and ANDA approvals. European markets generally impose stronger price controls and centralized or national reimbursement negotiations, which can accelerate erosion after generic entry.
Emerging-market demand can persist through lower-cost generic riluzole, but branded Rilutek has limited ability to sustain premium pricing where public reimbursement systems select products primarily on cost.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers for standard riluzole tablets are low. The active pharmaceutical ingredient is established, the dosage form is conventional, and generic manufacturers can use mature oral-solid-dose production capabilities.
Higher barriers exist for:
- Stable oral suspensions
- Rapidly dissolving oral films
- Taste masking
- Dose uniformity
- Moisture-sensitive packaging
- Specialized manufacturing equipment
- Consistent scale-up and commercial supply
These barriers can support formulation franchises, but they do not protect Rilutek tablets. A company evaluating the market would likely view conventional riluzole as a low-barrier generic opportunity and differentiated delivery systems as moderate-barrier specialty opportunities.
Key Takeaways
- Rilutek is the original branded riluzole tablet for ALS, approved by the FDA in 1995.
- Its NCE exclusivity and original patent protection have expired.
- Generic riluzole tablets are the central commercial threat and have already reshaped the product’s economics.
- Rilutek has no current patent estate that materially blocks standard generic entry.
- Tiglutik oral suspension and Exservan oral film compete with Rilutek through formulation differentiation.
- Sanofi does not separately disclose Rilutek revenue, preventing a precise product-level sales history.
- The brand’s financial trajectory is mature to declining, with residual cash flow but limited pricing power.
- The main value in the riluzole category has shifted from compound protection to delivery technology, patient access, and specialty distribution.
- Paragraph IV risk is low for the original tablet but may remain relevant for later oral suspension and oral film products.
- Generic tablets remain the lowest-cost treatment option, while differentiated formulations target ALS patients with swallowing difficulties.
FAQs About Rilutek Market and Patent Position
Is Rilutek still under patent protection?
No material U.S. patent protection currently blocks generic riluzole tablets. The original compound and tablet exclusivity have expired.
Is generic riluzole therapeutically equivalent to Rilutek?
FDA-approved generic riluzole tablets must meet applicable pharmaceutical-equivalence and bioequivalence requirements. They are intended to provide the same active ingredient, strength, dosage form, and clinical effect as the reference product.
Can patients substitute Rilutek with Tiglutik or Exservan?
Substitution is not automatically equivalent because Tiglutik is an oral suspension and Exservan is an oral film. A prescriber may need to authorize the dosage-form change, and reimbursement rules may differ.
Does Rilutek have biosimilar competition?
No. Rilutek is a small-molecule drug, not a biologic. It faces generic competition under the ANDA pathway rather than biosimilar competition under the Public Health Service Act.
What would increase the commercial value of a riluzole product?
The strongest opportunities are differentiated delivery systems for dysphagia, improved adherence, specialty-pharmacy support, reliable supply, and reimbursement advantages. New compound value would require clinical evidence materially beyond riluzole’s established survival benefit.
References
-
U.S. Food and Drug Administration. (1995). Rilutek (riluzole) tablets, NDA 20-599: Approval history and prescribing information. FDA.
-
Bensimon, G., Lacomblez, L., & Meininger, V. (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. New England Journal of Medicine, 330(9), 585-591.
-
U.S. Food and Drug Administration. (2018). Tiglutik (riluzole) oral suspension, NDA 208230: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2020). Exservan (riluzole) oral film, NDA 212640: Prescribing information. FDA.
-
Sanofi. (2023). Universal registration document and annual financial report 2023. Sanofi.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
Centers for Disease Control and Prevention. (2024). Amyotrophic lateral sclerosis surveillance and prevalence information. CDC.
